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Introduction
Malignant melanoma is a tumor of the melanocytes in
the skin and mucosal membranes. Approximately 3% of
malignant melanomas involve the female genital tract.
There are three histologic types of malignant melanoma:
superficial spreading, nodular, and acral lentiginous,
of which nodular melanomas have the worst prognosis.
Vulvar melanoma may develop from preexisting junc-
tional or compound nevi, as well as de novo from epi-
dermal melanocytes in the basal layer of the squamous
epithelium. Melanoma development in the vulva displays
interesting characteristics; although the vulva consti-
tutes only 2% of the body surface, 3–7% of malign
melanomas occur in the vulva. Melanoma of the vulva
is the second most common malignancy arising within
the vulva and accounts for 8–10% of all vulvar malig-
nancies [1]. The density (number per square unit of
body surface area) of cutaneous melanomas occurring
in various body areas has recently been evaluated [2],
and the results showed that the density of invasive
cutaneous melanomas on the face was 2.3 times higher
than the density on all other body skin areas. This over-
representation of melanomas on the facial skin is similar
to that seen for the vulva compared with the whole body
skin. The similarity in melanoma density between the
most sun-exposed and one of the most sun-shielded
areas of the body is of considerable interest for estab-
lishing other causative factors of melanogenesis, in
addition to UV radiation [3]. Malignant melanoma of
the vulva occurs in the labium majus in 34% of cases,
the labium minus in 29%, the clitoral area in 24%, and
in the midline structures (periurethral area, introitus,
posterior fourchette) in 13% [3]. Since 1861, more than
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1,800 cases of vulvar melanoma have been described
in the literature. Vulvar melanomas not only carry a poor
prognosis and show a tendency for local recurrence, but
also develop distant metastases through hematogenous
dissemination.
Primary malignant melanoma of the vagina is a
very rare tumor with fewer than 300 cases reported
worldwide. It accounts for less than 3% of all vaginal
malignancies and 0.3–0.8% of all malignant melanomas
[4]. The most common presenting symptoms are vaginal
bleeding, vaginal discharge or a palpable mass. As the
tumor may spread hematogenously, early metastases are
common and the prognosis is poor, with a reported 5-
year survival rate of 8.4% [5]. The tumor is primarily
found in the distal third (58% of cases) of the vagina and
mostly on the anterior wall (45% of cases) [6]. Conser-
vative wide local excision, radical surgical extirpation,
irradiation, and chemotherapy are the treatment options,
which can be used individually or in combination.
In this report, we present one case of vulvar and
four cases of vaginal malignant melanomas.
Case Reports
Case 1
A 58-year-old woman was referred to our hospital with
complaints of a palpable mass and itching in the vulva.
On vulvar examination, a papillomatous pigmented
lesion, 3 × 2 cm in size, was seen in the posterior
fourchette. Following vulvar biopsy, mucosal lentigi-
nous malignant melanoma was diagnosed. The tumor
was 2 mm at the deepest margin (Chung level III; Clark
level III, tumor fills papillary dermis, and extends to the
reticular dermis but does not invade it). There was no
significant family history, and no abnormalities were
detected on physical examination. Bilateral inguinal
lymph nodes were not palpable. She had undergone a
hysterectomy 12 years earlier, and her vagina and ova-
ries appeared atrophic. No palpable mass was detected
in either adnexal area. Vaginal cuff smears revealed 
no malignant cells, and thoraco-abdominopelvic com-
puted tomography (CT) produced no pathologic find-
ings. She was treated with wide local excision of the
tumor (excision of 2 cm from the outer limit and 2 cm
from the deep limit of tumor) and bilateral inguinal
lymph node dissection. No tumor tissue was present in
the surgical margins, and no lymphatic invasion was
found. The tumor was classified as stage II according to
International Federation of Gynecology and Obstetrics
(FIGO) staging system and stage IIA according to the
American Joint Commission on Cancer (AJCC) staging
system [1]. No adjuvant therapy was administered. 
No local or distant metastases were detected during her
first postoperative year.
Case 2
An 89-year-old woman was referred to our hospital
with complaints of a palpable vaginal mass, vaginal
bleeding, and dysuria. Her medical history included
hypertension, diabetes mellitus, and coronary artery dis-
ease. Inspection showed an ulcerated, infected, fragile
and hemorrhagic lesion, 3 cm in size, on the anterior
side of the lower third of the vagina. There were no
palpable inguinal lymph nodes. A biopsy of the lesion
was performed, and the pathology report indicated a
nodular malign melanoma. The histologic diagnosis was
confirmed by positive immunostaining with monoclonal
antibody to human melanoma (HMB-45). Imaging stud-
ies revealed no signs of metastases. She was treated
with wide local excision (excision of 2 cm from the outer
limit). Lymph node dissection was not performed. In
light of the patient’s age and existing comorbidities, a
radical approach was avoided in order to minimize the
surgery time and reduce the risk of increased comor-
bidity. Pathologic examination of the excised material
revealed a tumor thickness of 0.8 mm (Chung level II),
and the surgical margins were tumor-free. The tumor
was classified as FIGO stage I. The patient received no
adjuvant therapy. She was still alive, without local or
distant metastases, after 2 years.
Case 3
A 54-year-old woman, menopausal for 3 years, pre-
sented with a complaint of vaginal bleeding. Her med-
ical history was unremarkable, and there was no family
history of malignancy. Examination revealed a nodular,
necrotic lesion, 6 cm in size, on the anterior left side of
the lower third of the vagina and another irregular lesion,
4 cm in size, on the posterior side of the lower third. 
A cervical Papanicolaou test showed malignant infiltra-
tive cells. Imaging studies revealed no evidence of metas-
tases. An excisional biopsy of the lesions suggested
several possible diagnoses, including alveolar rhab-
domyosarcoma, undifferentiated leiomyosarcoma or
malignant melanoma. Immunohistochemistry showed
HMB-45- and S-100-positive staining, and the diag-
nosis was confirmed as malignant melanoma. Radical
hysterectomy and total vaginectomy were performed,
together with pelvic and inguinal lymph node dissection
and bilateral salpingo-oophorectomy. The postopera-
tive course was unremarkable. Histopathologic study of
the specimen revealed tumor-free surgical margins of
at least 10 mm laterally and 3 mm in depth. There were
no pelvic lymph node metastases. On microstaging,
the Breslow depth was 13 mm and Chung level was IV;
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the case was allocated AJCC stage IIB and FIGO stage I.
The patient received postoperative adjuvant therapy
with interferon alpha-2b, 20 MIU/m2/day, 5 days/week
for 1 month, followed by 3 days/week for a total of 12
weeks. Despite this treatment, CT scanning revealed lung
and liver metastases. Her condition rapidly worsened,
and she died 2 months later of widespread disease.
Case 4
A 41-year-old woman was referred to our hospital
because of vaginal bleeding. Vaginal inspection showed
an irregular mass, 4 × 4 cm in size, apparently arising
from the uterus. It was thought to be a degenerated
myoma, and vaginal myoma extirpation was, therefore,
performed. Pathologic diagnosis revealed malignant
melanoma, and immunohistochemistry demonstrated
HMB-45- and S-100-positive staining. CT examination
of the thorax, abdomen and pelvis revealed no signs of
metastases. Radical hysterectomy and total vaginectomy
were performed, together with pelvic and inguinal lymph
node dissection, and bilateral salpingo-oophorectomy.
Her postoperative course was unremarkable. The final
histopathology report confirmed nodular malignant
melanoma. The surgical margins were negative for
tumor cells, and no melanoma cells were seen in the
uterus. There were no pelvic lymph node metastases.
On microstaging, the Breslow depth was 12 mm. The
patient was considered as high risk for recurrence owing
to the tumor stage, according to Chung classification
(level IV), and she, therefore, received postoperative
adjuvant therapy with interferon alpha-2b, 20 MIU/m2/
day, 5 days/week for 1 month, followed by 3 days/week
for a total of 12 weeks. Thirteen months later, the cancer
was unfortunately found to have metastasized to the
brain, lung and liver. Her condition rapidly worsened,
and she died 3 weeks later of widespread disease.
Case 5
A 75-year-old woman was referred to our hospital
because of a palpable vaginal mass. Inspection showed
a nodular necrotic lesion, 2 cm in size, on the anterior
left side of the lower third of the vagina, near the ure-
thra. There were no palpable inguinal lymph nodes.
She had no systemic disease, and she had undergone
hysterectomy and bilateral salpingo-oophorectomy 25
years earlier. A biopsy of the lesion was performed, and
the pathology report indicated a malign mesenchymal
tumor. Imaging studies revealed no signs of metastases.
She was initially treated with wide local excision (excision
of 1 cm beyond the outer limit). The diagnosis of
nodular malignant melanoma was established from
the surgical specimen. Immunohistochemistry showed
vimentin- and S-100-positive staining. The Breslow
depth was 11 mm and Chung level was IV. However,
the surgical margins were positive for tumor cells, and
total vaginectomy was, therefore, performed. Her post-
operative course was unremarkable. Histopathologic
study of the latter specimen revealed tumor-free surgi-
cal margins, which were at least 11 mm laterally and
2 mm in depth. There were some remarkable histo-
logic findings, including 13 mitoses per 10 high-power
fields and the presence of vascular involvement. The
patient was considered to be at high risk; she received
postoperative adjuvant therapy with interferon alpha-
2b, 20 MIU/m2/day, 5 days/week for 1 month, followed
by 3 days/week for a total of 12 weeks. One month
after the completion of adjuvant therapy, CT scanning
revealed lung, pelvic and cerebral metastases, and the
patient subsequently died of widespread disease.
The Table shows the clinical data for these cases.
Discussion
Approximately 3% of malignant melanomas involve
the female genital tract. Melanoma of the vulva is the
second most common malignancy arising within the
vulva and accounts for 8–10% of all vulvar malignancies.
Parity, hormonal and genetic factors seem to be unre-
lated to the occurrence of vulvar melanoma [1]. In
addition, vulvar melanoma is likely to result from etio-
logic factors other than UV radiation; such factors could
be tissue-specific, or could derive from environmental
toxins, drugs or viruses [3]. Common presenting symp-
toms include a palpable vulvar mass, pain, bleeding,
itching, and (rarely) dysuria and ulceration. Our patient
with vulvar melanoma was presented with a palpable
mass and itching. An increased awareness of pigmented
vulvar lesions and a low clinical threshold for biopsy 
of such lesions may ultimately hold the best hope for
improving the prognosis in susceptible patients. The
main prognostic factors are demographic characteris-
tics (race, advanced age), tumor localization, presence
of groin node metastases, and various tumor charac-
teristics (thickness, ulceration, mitotic rate, histologic
type, DNA ploidy, angioinvasion, and macroscopic
amelanosis). Age, stage and lymph node involvement
were found to be significant factors affecting survival
in patients with vulvar melanoma [7].
Histologically, vulvar melanomas are mainly of the
mucosal lentiginous subtype, as seen in our patients.
In a study of 219 Swedish women with vulvar mela-
nomas, 57% of tumors were mucosal lentiginous, 22%
were nodular, 12% were unclassified, and only 4% were
superficial spreading melanomas. This was the reverse
of the order observed for cutaneous melanomas [8].
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The first case study of a primary vulvar melanoma
was published in the Lancet in 1861. Since 1861, more
than 1,800 cases of vulvar melanoma have been de-
scribed in the literature. Although the majority of these
genital tract lesions arise on the vulva and are unifocal,
Podczaski et al [9] reported a patient with multiple
malignant melanomas of the lower genital tract in 1990.
In 1997, Luxman et al [10] presented a case of uterine
metastasis from vulvar malignant melanoma. Recently,
Akoz et al [11] reported a synchronous cervical and
vulvar malign melanoma. These studies demonstrate
the importance of evaluating the entire genital system
in patients with vulvar melanoma.
One of the most dramatic differences between vulvar
and cutaneous melanomas is the recurrence rate. The
Swedish study [8] described an increased risk of ulcer-
ation, a vertical growth phase component, amelanosis,
and recurrence in vulvar melanomas. No signs of recur-
rence were seen at 1-year’s follow-up in our patient.
Because of the rarity of vulvar melanomas and the
inconsistency with which important prognostic factors
are reported, it is difficult to accurately evaluate sur-
vival statistics. The reported 5-year survival rates for
vulvar melanoma range from 27% to 60% [3]. This is 
in contrast with cutaneous melanoma, which has a 
5-year survival rate of 88%.
Treatment options range from local excision of the
tumor and sentinel lymph node dissection to radical re-
section involving en bloc vulvectomy and inguinofemoral
lymphadenectomy. The currently recommended surgi-
cal approaches include excision of the tumor and all
tissue that is 1 cm from the tumor’s outer limit (for
tumors with a Breslow thickness of 1 mm). Similarly,
excision of 2 cm from the outer limit and 1–2 cm from
the deep limit of the tumor (large local excision) is also
suggested for those with a Breslow thickness of 1–4 mm.
Radical excision, including the fascia, or vulvectomy
should be performed in the case of melanomas with
Breslow thickness > 4 mm. Elective node dissection
seems to offer no additional advantage in superficial
lesions < 0.76 mm thick, and its role in deeper lesions
is still uncertain. Because our patient’s tumor was 2 mm
at the deepest margin, elective lymph node dissection
was performed in addition to wide local excision.
Vulvar melanomas have an overall poor prognosis,
and there is a lack of consensus in the published litera-
ture regarding treatment options. Surgery is still the
best available treatment for the control and potential
cure of malignant melanomas. However, the therapy
should be tailored to meet the specific needs of indi-
vidual patients [12]. Dacarbazine is the most active
chemotherapeutic agent, which can produce response
rates of 15–25% [1].
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Primary malignant melanoma of the vagina is a
very rare tumor, with fewer than 300 cases reported
worldwide. It accounts for less than 3% of all vaginal
malignancies and for 0.3–0.8% of all malignant mela-
nomas [4]. As the vagina has a diffuse lymphatic plexus
and the tumor can spread hematogenously, early
metastases are common. Clinical diagnosis is often
made at an advanced stage with a variable degree 
of pigmentation, usually on the anterior aspect of the
vagina. However, no signs of metastases were detected
in our four patients with vaginal melanomas at the
time of diagnosis, and only one of them was alive with-
out local or distant metastases at the time of writing
this report. The most common presenting symptoms
are vaginal bleeding, vaginal discharge or a palpable
mass. The tumor is most commonly located in the dis-
tal third (58% of cases) of the vagina and mostly on
the anterior wall (45% of cases), as in three of our
patients with malignant melanomas of the vagina.
It may be difficult to distinguish between undiffer-
entiated carcinoma and sarcoma based on histopa-
thologic results, as in one of our patients with vaginal
melanoma (Case 3), because malignant melanomas
can display different morphologic patterns, including
small spindle-shaped or epithelioid cells. The presence
of melanin pigment is helpful for determining tumor
histogenesis, but amelanotic melanomas do not con-
tain any melanin pigment. In addition, biopsies taken
from necrotic tissues may be deceptive. Consequently,
biopsy results for malignant melanoma of the female
genital tract may be associated with misdiagnosis, and
immunohistochemistry assays should also be used to
confirm the diagnosis.
Prognostic factors have been difficult to identify;
previous reviews found tumor size to be one of the most
important, whereas tumor thickness was only a weak
predictor of survival [13,14]. Li et al [14] found a sig-
nificant difference in mean survival time between pa-
tients with tumor diameters of ≤ 2 cm and > 2 cm (27.7
months and 9.7 months, respectively). They also found
that tumor diameter and surgery were significantly
related to survival time, and that the prognosis could
be improved if the disease was diagnosed early and
combined modality therapy was used, with the empha-
sis on surgery. There is no obvious relationship between
overall outcome and age, parity, FIGO stage, or location.
Histologic features, such as cell type, mitotic count,
ulceration, vessel and lymphatic involvement, or ame-
lanosis do not seem to correlate with patient survival
[15,16]. Among the four vaginal melanoma patients in
this study, three (Cases 3, 4 and 5), who had relatively
larger lesions compared with Case 2, died of widespread
disease during the follow-up period. Case 2 was also
diagnosed earlier, with Chung level II, whereas others
were diagnosed with Chung level IV tumors.
As primary malignant melanoma of the vagina is a
very rare gynecologic malignancy, limited data are avail-
able on which to base recommendations for the primary
management of patients. Several treatment options exist,
but no standard approach has been established. The
spectrum of surgical therapies ranges from conserva-
tive surgery, such as wide local excision or total vaginec-
tomy, to radical extirpation with en bloc removal of
involved pelvic organs. Previous studies have recom-
mended wide local excision with adjuvant radiother-
apy, and radical surgery with adjuvant radiotherapy as
second-line therapy. Both procedures result in similar
5-year survival rates. Some authors have recommended
radical surgery [17–19], but more recent publications
have reported that wide local excision is associated
with equivalent survival rates [5,20–22]. Geisler et al
[17] advised primary pelvic exenteration for vaginal
melanomas > 3 mm of invasion, and showed that a 5-
year survival rate of 50% could be obtained if the pelvic
nodes were free of metastases. Stellato et al [18] per-
formed very radical surgery in a case with a primary
melanoma of the upper third of the vagina with ure-
thral and urinary bladder infiltration. Following pre-
liminary bilateral pelvic lymphadenectomy, anterior
exenteration and urinary bladder reconstruction, the
patient was in a partial remission 1 year after surgical
treatment, though she developed liver metastases 
4 months after surgery. Raber et al [19] claimed that
radical surgery achieved superior results. Cobellis et al
[21] suggested that primary treatment should consist
of wide local excision of the tumor. Buchanan et al
[22] also stated that it was difficult to support the use
of radical surgery as primary treatment for vaginal
melanoma, unless it was necessary to achieve clear
tumor margins. Irvin et al [5] were unconvinced about
the value of extended surgical procedures, given the
high incidence of metastases that remain undetected
at initial diagnosis of this disease. A failure to detect
metastases during the preoperative investigations can
be deceptive; before making a decision to treat a vagi-
nal malignant melanoma, undetectable distant metas-
tases should be considered. No distant metastases
were detected during the preoperative period in any of
the patients with vaginal malignant melanomas pre-
sented in this report. Although local control of the
melanoma could be maintained, distant metastases to
the lung, liver and brain still occurred. The role of elective
lymph node dissection also remains controversial, as
does the dissection of lymph nodes that are clinically
negative for melanoma of the vagina. Distant metas-
tases are very common at presentation, regardless of
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the regional lymph node status. None of our patients
who received lymph node dissection had positive nodes.
Coleman et al [23] reported that routine lymphatic
dissection is impractical, given the rich anastomotic
nature of the vaginal lymphatics and the imperfect pre-
diction of limited negative sampling. Miner et al [24]
also suggested that elective pelvic lymph node dissec-
tion was not essential because of the low rate of lymph
node metastasis. Sentinel lymph node mapping has
recently gained popularity. Siu et al [25] recommended
excluding lymphatic and distant metastases before
embarking on radical surgery. They presented the first
case of laparoscopic ultrasonographic detection of
metastatic pelvic lymph nodes in a patient with vaginal
melanoma.
In the current study, a radical treatment approach
was chosen in Cases 3 and 4, and lymph node dis-
section was performed. One reason for choosing this
modality was the absence of any clinically observed
distant metastases during the preoperative evaluation.
In addition, malignant infiltrative cells in Case 3 were
seen in the Papanicolaou test, and the lesion in Case 
4 was thought to arise from the uterus. The aim was 
to improve patients’ survival by providing local tumor
evaluation. We administered immunotherapy with inter-
feron alpha-2b, which has been shown to improve
relapse-free and overall survival in patients with high-
risk cutaneous melanomas, to patients of Cases 3, 4
and 5 to reduce the risk of metastases. In Cases 2 and
5, lymph node dissection was not performed because
of the patients’ ages, the risk of increasing comorbid-
ity, and the low rate of lymph node metastasis. The
effect of lymph node dissection in vaginal melanomas
is still uncertain.
In conclusion, the prognosis for malignant mela-
noma of the female genital tract is poor, regardless 
of the treatment delivered, though it can be improved
if the disease is diagnosed early. All patients and phy-
sicians should be educated about the possibilities 
of vulvar and vaginal involvement, and physicians
should be encouraged to include a genital examina-
tion when performing routine total body skin exami-
nations, especially in elderly women. As there is
currently no proven standard therapy, therapy should
be tailored to meet the specific needs of individual
patients.
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